Amarin's AMR101 orders ANCHORs aweigh for lipid disorders
This article was originally published in Scrip
Executive Summary
Amarin's course is set fair for approval of its hypolipaemic AMR101 after the Phase III ANCHOR trial hit all its primary and secondary endpoints at both doses tested.